Trial Profile
A Randomized, Open-Label, 4-Group, 2-Period Replicate Design Study to Evaluate Within- and Between-Subject Variability in Exposure of Two Lots of E5501 20 mg Tablets, Administered as Single Doses of 40 mg, in the Fasted and Fed Conditions to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2014
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 18 Sep 2014 New trial record